These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35173552)

  • 1. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction.
    Zhang N; Ma Q; You Y; Xia X; Xie C; Huang Y; Wang Z; Ye F; Yu Z; Xie X
    Int J Biol Sci; 2022; 18(3):1271-1287. PubMed ID: 35173552
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
    Alex L; Russo I; Holoborodko V; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis.
    Glezeva N; Voon V; Watson C; Horgan S; McDonald K; Ledwidge M; Baugh J
    J Card Fail; 2015 Feb; 21(2):167-77. PubMed ID: 25459685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune profiling of murine cardiac leukocytes identifies triggering receptor expressed on myeloid cells 2 as a novel mediator of hypertensive heart failure.
    Smart CD; Fehrenbach DJ; Wassenaar JW; Agrawal V; Fortune NL; Dixon DD; Cottam MA; Hasty AH; Hemnes AR; Doran AC; Gupta DK; Madhur MS
    Cardiovasc Res; 2023 Oct; 119(13):2312-2328. PubMed ID: 37314125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction.
    Tamaki S; Mano T; Sakata Y; Ohtani T; Takeda Y; Kamimura D; Omori Y; Tsukamoto Y; Ikeya Y; Kawai M; Kumanogoh A; Hagihara K; Ishii R; Higashimori M; Kaneko M; Hasuwa H; Miwa T; Yamamoto K; Komuro I
    PLoS One; 2013; 8(7):e68893. PubMed ID: 23894370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction.
    Zhang L; Chen J; Yan L; He Q; Xie H; Chen M
    Front Pharmacol; 2021; 12():646240. PubMed ID: 34177571
    [No Abstract]   [Full Text] [Related]  

  • 7. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype.
    Li Y; Kubo H; Yu D; Yang Y; Johnson JP; Eaton DM; Berretta RM; Foster M; McKinsey TA; Yu J; Elrod JW; Chen X; Houser SR
    Am J Physiol Heart Circ Physiol; 2023 Apr; 324(4):H443-H460. PubMed ID: 36763506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac sympathetic overdrive, M2 macrophage activation and fibroblast heterogeneity are associated with cardiac remodeling in a chronic pressure overload rat model of HFpEF.
    Sun F; Yuan L; Wang Z; Cui X; Lv N; Zhang T; Zhang Y; Cai J
    Front Pharmacol; 2024; 15():1364758. PubMed ID: 38860171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preload dependence in an animal model of mild heart failure with preserved ejection fraction (HFpEF).
    Jacobsen JCB; Schubert IH; Larsen K; Terzic D; Thisted L; Thomsen MB
    Acta Physiol (Oxf); 2024 Mar; 240(3):e14099. PubMed ID: 38230889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.
    Glezeva N; Baugh JA
    Heart Fail Rev; 2014 Sep; 19(5):681-94. PubMed ID: 24005868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction.
    Gao C; Xiong Z; Liu Y; Wang M; Wang M; Liu T; Liu J; Ren S; Cao N; Yan H; Drucker DJ; Rau CD; Yokota T; Huang J; Wang Y
    Circ Res; 2024 Aug; 135(5):614-628. PubMed ID: 39011638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in extracardiac mechanisms for heart failure with preserved ejection fraction.
    Wang S; Xiao Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 47(12):1733-1739. PubMed ID: 36748385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Kanagala P; Cheng ASH; Singh A; Khan JN; Gulsin GS; Patel P; Gupta P; Arnold JR; Squire IB; Ng LL; McCann GP
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2291-2301. PubMed ID: 30772227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockout of MD1 contributes to sympathetic hyperactivity and exacerbates ventricular arrhythmias following heart failure with preserved ejection fraction via NLRP3 inflammasome activation.
    Yang HJ; Kong B; Shuai W; Zhang JJ; Huang H
    Exp Physiol; 2020 Jun; 105(6):966-978. PubMed ID: 32240565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction.
    Zuo GF; Wang LG; Huang L; Ren YF; Ge Z; Hu ZY; Zhang JJ; Chen SL
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166979. PubMed ID: 38065272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmasking of oestrogen-dependent changes in left ventricular structure and function in aged female rats: a potential model for pre-heart failure with preserved ejection fraction.
    Bustamante M; Garate-Carrillo A; R Ito B; Garcia R; Carson N; Ceballos G; Ramirez-Sanchez I; Omens J; Villarreal F
    J Physiol; 2019 Apr; 597(7):1805-1817. PubMed ID: 30681142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction.
    Kanashiro-Takeuchi RM; Takeuchi LM; Dulce RA; Kazmierczak K; Balkan W; Cai R; Sha W; Schally AV; Hare JM
    Am J Physiol Heart Circ Physiol; 2023 Jun; 324(6):H739-H750. PubMed ID: 36897749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.